# Thermal Ablation Followed by Immunotherapy for HCC

> **NCT03864211** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Xiangya Hospital of Central South University** · enrollment: 145 (actual)

## Conditions studied

- Hepatocellular Carcinoma Non-resectable

## Interventions

- **PROCEDURE:** Thermal ablation
- **DRUG:** Toripalimab

## Key facts

- **NCT ID:** NCT03864211
- **Lead sponsor:** Xiangya Hospital of Central South University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-06-15
- **Primary completion:** 2023-05-30
- **Final completion:** 2023-05-30
- **Target enrollment:** 145 (ACTUAL)
- **Last updated:** 2022-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03864211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03864211, "Thermal Ablation Followed by Immunotherapy for HCC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03864211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*